Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2019 / Mar / Biomarkers Beyond Our Wildest Dreams
Omics Metabolomics Lipidomics Chromatography Liquid Chromatography Mass Spectrometry Translational Science

Biomarkers Beyond Our Wildest Dreams

Could glycosylation patterns associated with a sleep behavior disorder predict the onset of neurodegenerative disease?

By Luke Turner 03/20/2019 1 min read

Share

For someone with idiopathic REM sleep behavior disorder (iRBD), dreams can come true – literally. A loss of muscle paralysis during rapid eye movement (REM) sleep can cause patients with the disorder to physically act out their dreams. There is a pressing need to identify biomarkers that could help diagnose this condition – not just because the disorder itself can affect overall health, but also because iRBD is now considered to be an early indicator of an α-synucleinopathy related to various neurodegenerative diseases, such as Parkinson’s. Now, research that focuses on glycosylation patterns has identified certain N-glycan structures that could serve as diagnostic biomarkers for patients with iRBD (1).

Although the quest for iRBD biomarkers has recently been driven by proteomics, a growing body of evidence has shown that glycosylation plays an important role in dynamic disease mechanisms and the onset of various pathological conditions. This led the researchers to compare the glycosylation patterns of nine iRBD patients with those of 10 healthy controls using liquid chromatography and mass spectrometry (LC-MS). The analysis of permethylated glycans from blood sera found 59 N-glycan structures in the healthy cohort and 56 in the iRBD cohort. Sixteen of these N-glycan structures were significantly altered in the patients with iRBD, including the HexNAc6Hex6 species, which was only present in this group.

In addition, seven N-glycan isomers differed significantly between the two cohorts. Of these, the greatest differences were found in levels of HexNAc4 Hex5 Fuc1 NeuAc1 and HexNAc4 Hex5 Fuc1 NeuAc2, which were higher in the iRBD group. By acting as diagnostic biomarkers for iRBD, these findings could provide an important window into the underlying neurodegenerative diseases such patients may possess.

To achieve accurate separation, identification, and quantification of isomeric glycans, the researchers needed to address issues with the ability of LC-MS to separate isomers. “Our group has adopted a sophisticated and advanced approach to optimize isomeric separation by using porous graphitized carbon stationary phase under a high temperature of 75°C,” the authors explained in their study. The approach facilitated the “reliable identification and characterization of glycan structures, as well as precise and accurate quantitation of isomeric structures.”

They emphasize that further studies with larger sample sizes are needed to confirm the reproducibility of their findings. Eventually, though, their discovery that a link could exist between glycosylation patterns and the presence of iRBD could be crucial for identifying patients at increased risk of neurodegenerative disorders. Although the potential for such predictions raises ethical questions around selecting patients to be tested – and mitigating the possible psychological effects of the results – the potential for developing molecular therapeutic targets to combat neurodegeneration is nevertheless enticing.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. X Dong et al., “LC-MS/MS glycomics of idiopathic rapid eye movement sleep behavior disorder”, Electrophoresis, 39, 3096–3103 (2018). PMID: 30168606.

About the Author(s)

Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

More Articles by Luke Turner

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.